PTC Therapeutics Appoints Shane Kovacs as Chief Financial Officer

      PTC Therapeutics Appoints Shane Kovacs as Chief Financial Officer

PR Newswire

SOUTH PLAINFIELD, N.J., June 3, 2013

SOUTH PLAINFIELD, N.J., June 3, 2013 /PRNewswire/ --PTC Therapeutics, Inc.
(PTC) today announced the appointment of Shane Kovacs as Chief Financial
Officer, reporting to Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. Mr.
Kovacs will be responsible for all finance-related activities at PTC.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO )

"We are excited to welcome Shane as a member of our senior management team,"
stated Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. "His extensive
background in both the finance and biotechnology sectors makes him a valuable
addition to PTC."

Prior to joining PTC, Mr. Kovacs served as Managing Director, Health Care
Investment Banking at Credit Suisse. In this capacity, he focused on advising
life sciences companies on transactions ranging from equity and debt
financings to mergers and acquisitions. He joined Credit Suisse in 2004 and
held various positions of increasing responsibility. Prior to Credit Suisse,
Mr. Kovacs worked in investment banking at National Bank Financial in Toronto.
Mr. Kovacs received an MBA from Richard Ivey School of Business at the
University of Western Ontario and a Bachelors of Engineering in Chemical
Engineering and a Bachelors of Sciences in Life Sciences from Queen's
University in Kingston, Ontario. Mr. Kovacs is also a CFA Charterholder.

"I had the pleasure of working closely with PTC's leadership team in my prior
role at Credit Suisse," stated Mr. Kovacs. "I am both honored and excited by
the opportunity to join Stuart and the entire PTC team as they strive to
impact the lives of patients with life-threatening conditions."

About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery, development, and
commercialization of orally administered small-molecule drugs that target
post-transcriptional control processes. Post-transcriptional control processes
regulate the rate and timing of protein production and are of central
importance to proper cellular function. PTC's internally discovered pipeline
addresses multiple therapeutic areas, including rare genetic disorders,
oncology and infectious diseases. PTC has developed proprietary technologies
that it applies in its drug discovery activities and are the basis for
collaborations with leading biopharmaceutical companies. For more information,
visit the company's web site at www.ptcbio.com.

SOURCE PTC Therapeutics, Inc.

Website: http://www.ptcbio.com
Contact: Jane Baj, PTC Therapeutics, Inc., 908-912-9167; or Sheryl Seapy, Pure
Communications, sheryl@purecommunicationsinc.com